Angiogenesis inhibitors in clinical development; where are we now and where are we going?

F A L M Eskens, F A L M Eskens

Abstract

Angiogenesis is crucial for tumour growth and the formation of metastases. Various classes of angiogenesis inhibitors that are each able to inhibit one of the various steps of this complex process can be distinguished. Results from clinical studies with these agents are summarised. In general, it has been shown that most angiogenesis inhibitors can be safely administered, but that tumour regressions are rare. Combining angiogenesis inhibitors with cytotoxic chemotherapy can enhance anticancer activity. Recently, some promising data with regard to clinical efficacy have been presented. While performing clinical studies with angiogenesis inhibitors, defining biological activity is crucial, but thus far no validated techniques are available. It is conceivable that in the near future various classes of angiogenesis inhibitors will be combined in an attempt to further improve antiangiogenic and anticancer activity.

References

    1. Beerepoot L, Witteveen P, Groenewegen G, Fogler W, Sim B, Sidor C, Phillips E, Zonnenberg B, Schramel F, Gebbink M, Voest E (2001) Preliminary results of a phase I trial of recombinant human angiostatin by twice-daily subcutaneous injection in patients with advanced cancer. Proc AACR-NCI-EORTC (abstract 34)
    1. Bhargava P, Marshall J, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong V, Kato A, Hawkins M (1999) A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5: 1989–1995
    1. Blumenschein G, Fossella F, Pisters K, Khuri F, Lu C, Kies M, Glisson B, Zinner R, Crane E, Schaerer R, Dordal M, Goodin T, Hong W, Herbst R (2002) A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc Am Soc Clin Oncol 21: 314a (abstract 1254)
    1. Brahmer J, Kelsey S, Scigalla P, Hill G, Bello C, Elza-Brown K, Donehower R (2002) A phase I study of SU6668 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 21: 84a (abstract 335)
    1. Britten C, Rosen L, Kabbinavar F, Rosen P, Mulay M, Hernandez L, Brown J, Bello C, Kelsey S, Scigalla P (2002) Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proc Am Soc Clin Oncol 21: 28b (abstract 1922)
    1. Burnstein H, Parker L, Savoie J, Younger J, Kuter I, Ryan P, Garber J, Campos S, Shulman L, Harris L, Gelman R, Winer E (2002) Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 76(Suppl 1): S115 76: 115a (abstract 446)
    1. De Vos F, Hoekstra R, Gietema J, Eskens F, van der Gaast A, Carr R, Glad-Anderson S, Humerickhouse R, Groen H, de Vries E, Verweij J (2002) A phase I dose escalating study of the angiogenesis inhibitor thrombospondinmimetic (ABT-510) in patients with advanced cancer. Proc Am Soc Clin Oncol 21: 82a (abstract 324)
    1. DelProposto Z, LoRusso P, Latif Z, Morton P, Wheeler C Barge A, Evelhoch J (2002) MRI evaluation of the effects of vascular targeting agent ZD6126 on tumor vasculature. Proc Am Soc Clin Oncol 21: 111a (abstract 440)
    1. DeMoraes E, Fogler W, Grant D, Wahl M, Leeper D, Zrada S, Malin A, Connors S, Fortier A, Dabrow M, Sidor C, Capizzi R (2001) Recombinant human angiostatin (rhA): a phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc Am Soc Clin Oncol 20: 3a (abstract 10)
    1. Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK (2001) Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 7: 2971–2976
    1. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 15: 3408–3416
    1. Drevs J, Mross K, Medinger M, Mueller M, Laurent D, Reitsma D, Henry A, Xia J, Marme D, Unger C (2003) Phase I dose escalation and pharmacokinetic study of the VEGF inhibitor PTK787/ZK222584 in patients with liver metastases. Proc Amer Soc Clin Oncol 22: 284 (abstract 1142)
    1. Drevs J, Schmidt-Gersbach C, Mross K, Medinger M, Mueller M, Steward W, Laurent D, Lee L, Dugan M, Henry A, Marme D, Unger C (2002) Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in two clinical phase I trials. Proc Am Soc Clin Oncol 21: 85a (abstract 337)
    1. Dupont J, Camastra D, Gordon M, Mendelson D, Murren J, Hsu A, Lucarelli A, Cedarbaum J, Spriggs D (2003) A phase I study of VEGF trap in patients with solid tumors and lymphoma. Proc Am Soc Clin Oncol 22: 194 (abstract 776)
    1. Eder J, Supko J, Clark J, Puchalski T, Garcia-Carbonero R, Ryan D, Shulman L, Proper J, Kirvan M, Rattner B, Connors S, Keogan M, Janicek M, Fogler W, Schnipper L, Kinchla N, Sidor C, Phillips N, Folkman J, Kufe D (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20: 3772–3784
    1. Eskens F, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom A (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39: 917–926
    1. Faivre S, Chieze S, Marty M, Hammershaimb L, Pluda J, Lozahic S, Armand J, Raymond E (2003) Safety profile and pharmacokinetic analysis of medi-522, a novel humanized monoclonal antibody that targets integrin αvβ3 receptor, in patients with refractory solid tumors. Proc Am Soc Clin Oncol 22: 208 (abstract 832)
    1. Gadgeel S, LoRusso P, Wozniak A, Wheeler C (2002) A dose-escalation study of the novel vascular targeting agent ZD6126 in patients with solid tumors. Proc Am Soc Clin Oncol 21: 110a (abstract 438)
    1. Galbraith S, Rustin G, Lodge M, Taylor N, Stirling J, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani A (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on human tumour microcirculation assessed by dynamic enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 20: 3826–3840
    1. Gordon MS, Margolin K, Talpaz M, Sledge Jr GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–850
    1. Gordon MS, Mendelson D, Guirguis M, Knight R, Humerickhouse R, Stopeck A, Wang Q (2003) ABT-510, an anti-angiogenic, thrombospondin-1 (TSP-1) mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomized phase 1b trial. Proc Am Soc Clin Oncol 22: 195 (abstract 780)
    1. Gutheil J, Campbell T, Pierce P, Watkins J, Huse W, Bodkin D, Cheresh D (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6: 3056–3061
    1. Hansma A, Hoekman K, Broxterman H, Kievit E, van der Horst I, Boven E, Schalkwijk C, Pinedo H (2002) A phase I study of rhEndostatin: continuous intravenous (iv) followed by subcutaneous (sc) administration. Proc Am Soc Clin Oncol 21: 110a (abstract 436)
    1. Herbst R, Hess K, Tran H, Tseng J, Mullani N, Charnsangavej C, Madden T, Davis D, McConkey D, O'Reilly M, Ellis L, Pluda J, Hong W, Abbruzzese J (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20: 3792–3803
    1. Holden S, Morrow M, O'Bryant C, Pluda J, Eckhardt S (2002) Correlative biological assays to guide dose escalation in a phase I study of the antiangiogenic αVβ3 and αVβ5 integrin antagonist EMD121974 (EMD). Proc Am Soc Clin Oncol 21: 28a (abstract 110)
    1. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Griffing S, Novotny W, Holmgren E, Kabbinanvar F (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol (abstract 3646)
    1. Hurwitz H, Holden S, Eckhardt S, Rosenthal M, de Boer R, Rischin D, Green M, Basser R (2002) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc Am Soc Clin Oncol 21: 82a (abstract 325)
    1. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60–65
    1. Klagsbrun M, D' Amore P (1996) Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7: 259–270
    1. Kuenen B, Rosen L, Smit E, Parson M, Levi M, Ruijter R, Huisman H, Kedde M, Noordhuis P, van der Vijgh W, Peters G, Cropp G, Scigalla P, Hoekman K, Pinedo H, Giaccone G (2002a) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20: 1657–1667
    1. Kuenen B, Ruijter R, Hoekman K, Scigalla P, Giaccone G, Pinedo H (2002b) Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies. Proc Am Soc Clin Oncol 21: 110a (abstract 437)
    1. Langmuir V, Cobleigh M, Herbst R, Holmgren E, Hurwitz H, Kabbinavar F, Miller K, Novotny W (2002) Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Am Soc Clin Oncol 21: 9a (abstract 32)
    1. Logothetis C, Wu K, Finn L, Daliani D, Figg W, Ghaddar H, Gutterman J (2001) Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7: 1198–1203
    1. Manning W, Bello C, Deprimo S, Fletcher J, Fletcher C, Van Den Abbeele A, Cohen D, Scigalla P, Cherrington J, Demetri G (2003) Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients (pts) with imitanib-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22: 192 (abstract 768)
    1. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19: 851–856
    1. Mendel D, Laird A, Xin X, Li G, Schreck R, Carver J, Louie S, Sukbuntherng J, Plise E, Kelsey S, Scigalla P, Cherrington J (2002) Development of a preclinical pharmacokinetic/pharmacodynamic relationship for the angiogenesis inhibitor SU11248, a selective inhibitor of VEGF and PDGF receptor tyrosine kinases in clinical development. Proc Am Soc Clin Oncol 21: (abstract 94)
    1. Miller K (2003) E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3: 421–422
    1. Miller K, Rugo H, Cobleigh M, Marcom P, Chap L, Holmes F, Fehrenbacher L, Overmoyer B, Reimann J, Vassel A, Langmuir V (2002) Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 76(Suppl 1): S37 (abstract 36)
    1. Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto M, Yamamda Y, Tamura T (2003) A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474 in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 22: 194 (abstract 778)
    1. Patel S, Jenkins J, Papadopolous N, Burgess M, Plager C, Gutterman J, Benjamin R (2001) Pilot study of vitaxin – an angiogenesis inhibitor – in patients with advanced leiomyosarcomas. Cancer 92: 1347–1348
    1. Posey J, Ng T, Yang B, Khazaeli M, Carpenter M, Fox F, Needle M, Waksal H, LoBuglio A (2003) A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9: 1323–1332
    1. Radema S, Beerepoot L, Witteveen P, Gebbink M, Wheeler C, Voest E (2002) Clinical evaluation of the novel vascular targeting agent ZD6126: assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 21: 110a (abstract 439)
    1. Raymond E, Faivre S, Vera K, Delbaldo C, Robert C, Spatz A, Bello C, Brega N, Scigalla P (2003) Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor in patients with advanced cancers. Proc Am Soc Clin Oncol 22: 192 (abstract 769)
    1. Rosen L, Mulay M, Long J, Wittner J, Brown J, Marino AM, Bello C, Walter S, Scigalla P, Zhu J (2003) Phase I trial of SU11248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22: 191 (abstract 765)
    1. Rosen L, Rosen P, Kabbinavar F, Mulay M, Mickey J, Hernandez L, Brown J, Alexander J, Bello C, Cropp G, Kelsey S, Scigalla P (2001) Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 20: 97a (abstract 383)
    1. Rustin G, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G (2003) 5,6-dimethylxantenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88: 1160–1167
    1. Rustin G, Price P, Stratford M, Galbraith S, Anderson H, Folkes L, Robbins A, Senna L (2001) Phase I study of weekly intravenous combretastatin A4 phosphate (CA4P): pharmacokinetics and toxicity. Proc Am Soc Clin Oncol 20: 99a (abstract 392)
    1. Stadler W, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang N (1999) Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 17: 2541–2545
    1. Stevenson J, Gallagher M, Sun W, Algazy K, Vaughn D, Haller D, Hiller K, Halloran L, O'Dwyer P (2000) Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an iv bolus on a daily X5 schedule every 21 days. Proc Am Assoc Cancer Res 11: 544 (abstract 3469)
    1. Steward W, Thomas A, Morgan B, Wiedenmann B, Bartel C, Vanhoefer U, Trarbach T, Riedel U, Laurant D, Reitsma D (2003) Extended phase I/II study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222854 in combination with oxaliplatin/5-fluorouracil/leucovorin as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 22: 274 (abstract 1098)
    1. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A (2003) Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8: 2798–2805
    1. Thomas A, Morgan B, Drevs J, Jivan A, Buchert M, Horsfield M, Hennig J, Mross K, Henry K, Ball H, Peng B, Fuxius S, Unger S, O'Byrne K, Laurent D, Dugan M, Steward W (2001) Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 20: 71a (abstract 79)
    1. Tolcher A, Forero L, Celio P, Hammond L, Patnaik A, Hill M, Verat-Follet C, Haacke M, Besenval M, Rowinsky E (2003) Phase I, pharmacokinetic and DCE-MRI correlative study of AVE6082A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. Proc Am Soc Clin Oncol 22: 208 (abstract 834)
    1. Tolcher A, Karp D, O'Leary J, DeBono J, Caulkins J, Molpus K, Sutula K, Ferrante K, Gualberto A, Noe D, Huberman M, Rowinsky E (2002) A phase I and biological correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21: 84a (abstract 334)
    1. Toner G, Mitchell P, De Boer R, Gibbs P, Hicks R, Scott A, McArtur G, Brega N, Massimini G, Scigalla P (2003) PET imaging study of SU112248 in patients with advanced malignancies. Proc Am Soc Clin Oncol 22: 191 (abstract 767)
    1. Tran H, Herbst R, Xiong H, Madden T, Mulani N, Faria S, Kim K, Charnsangavej C, O'Reilly M, Abbruzzese J (2002) Phase I trial of recombinant human endostatin (rHu-endo) administered by continuous infusion (CI) intravenously (IV) in patients with solid tumors: a preliminary report. Eur J Cancer 38(Suppl 7): S73 22: 285 (abstract 230)
    1. Trarbach T, Schleucher N, Riedel U, Tewes M, Souppart C, Reitsma D, Seeber S, Laurant D, Vanhoefer U (2003) Phase I/II study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222854 in combination with irinotecan/5-fluorouracil/leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22: 285 (abstract 1144)
    1. Ueda Y, Shimoyama T, Murakami H, Yamamoto N, Yamada Y, Tamura T (2002) Phase I study of TSU-68, VEGF receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Proc Am Soc Clin Oncol (abstract 443) 21: 111a
    1. Voest E, Beerepoot L, Groenewegen G, Fogler W, Kim Lee Sim B, Sidor C, Phillips E, Zonnenberg B, Schramel F, Gebbink M, Witteveen P (2002) Phase I trial of recombinant human angiostatin by twice-daily subcutaneous injection in patients with advanced cancer. Proc Am Soc Clin Oncol 21: 81a (abstract 322)
    1. Yang J, Haworth L, Steinberg S, Rosenberg S, Novotny W (2002) A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc Am Soc Clin Oncol 21: 54 (abstract 15)
    1. Yung W, Friedman H, Conrad C, Reardon D, Provencale J, Jackson E, Leeds N, Serrajudin H, Laurant D, Reitsma D (2003) A phase I trial of single-agent PTK787/ZD222854 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Proc Am Soc Clin Oncol 22: 99 (abstract 395)
    1. Yung W, Friedman H, Jackson E, Provenzale J, Leeds N, Conrad C, Walker A, Henry A, Huang J, Laurent D, Dugan M (2002) A phase I trial of PTK787/ZD22854, a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc Am Soc Clin Oncol 21: 79a (abstract 315)

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa